full
border
#666666
https://www.arboretumvc.com/wp/wp-content/themes/zap-installable/
https://www.arboretumvc.com/wp/
#ffffff
style1

18
Jul

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, and Strata Oncology, Inc., a precision oncology company, have entered into a collaborative agreement to accelerate patient enrollment in Puma’s ongoing Phase II SUMMIT trial of PB272 (neratinib). The SUMMIT trial is a global, multi-histology, open-label, precision-medicine ‘basket’ study evaluating the safety and efficacy of neratinib in patients with a wide variety of solid tumors with activating EGFR, HER2 or HER4 mutations.
Link

0 Comments
11
Jul

Ebb Therapeutics, a medtech start-up initially focused on the development of innovative medical devices that help the millions of U.S. insomnia sufferers to more quickly find deeper, more restorative sleep, announced today the appointment of Elise Wilfinger as its Chief Marketing Officer.

Link

0 Comments
23
May

Strata Oncology, a precision oncology platform company, today announced the close of a $26 million USD Series B funding round. New investors Pfizer Ventures, Merck Global Health Innovation Fund, Deerfield Management and Renaissance Venture Capital Fund were joined by existing investors Arboretum Ventures and Baird Capital.
Link

Merck, Pfizer power tumor profiling firm Strata to $26M round – FierceBiotech Article
Link

0 Comments
18
May

AT&T and Aira extend their agreement as Aira made AT&T its global data provider as it begins to take the service to Australia, Canada and the U.K. This comes at a meaningful time. Today marks the 7th Global Accessibility Awareness Day (GAAD). The purpose of GAAD is to get everyone talking, thinking, and learning about digital access and inclusion for people with disabilities.
Link

0 Comments
30
Apr

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of NxThera. The company developed the Rezūm® system, a minimally invasive therapy (MIT) for patients with symptomatic benign prostatic hyperplasia (BPH). With the completion of the acquisition, NxThera will become part of the Boston Scientific Urology and Pelvic Health business.
Link

0 Comments
scrollauto
Loading posts...
link_magnifier
#ffffff
on
loading
off